Innovation Pharmaceuticals Inc (IPIX)

[georgejjl]

Brilacidin lotion as topical agent for atopic dermatitis (ecxema)

Phosphodiesterase inhibition assays demonstrated that Brilacidin inhibits both PDE4B2 (IC50 of 2.5 ± 0.21µM; n=5) and PDE3A (IC50 of 1.5 ± 0.2µM; n=4) in a dose dependent manner.

The PDE-Glo phosphodiesterase assay was performed using 8ng of PDE4B2 and 2.75ng of PDE3A, respectively, with 1µM cAMP substrate and indicated amount of Brilacidin.

Brilacidin and PDE4B2 and PDE3A, respectively, were mixed and pre-incubated at room temperature for 15minutes. Substrate was added and the reaction was incubated for 7 minutes at room temperature.

Both oral Prurisol and a topical formulation of Brilacidin may prove beneficial in treating atopic dermatitis

See Page 15

https://static1.squarespace.com/static/5715352e20c647639137f992/t/583c308f6a4963d2568f5fb1/1480339603725/11.27.16+Cellceutix_Corporate_Slide+Deck_MULTIDISCIPLINARY_November+2016+Website+Vers.pdf

Pfizer will acquire Anacor for $99.25 per Anacor share, in cash, for a total transaction value, net of cash, of approximately $5.2 billion

Anacor’s flagship asset, crisaborole, a differentiated non-steroidal topical PDE4 inhibitor with anti-inflammatory properties, is currently under review by the U.S. FDA for the treatment of mild-to-moderate atopic dermatitis, commonly referred to as eczema.

https://www.pfizer.com/news/press-release/press-release-detail/pfizer_to_acquire_anacor

Good luck and GOD bless,

George